Bicara Therapeutics Stock

Bicara Therapeutics is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology.

Sign up today and learn more about Bicara Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Bicara Therapeutics Stock

Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.

Funding History

March 2021$40.0M
March 2023$108M

Management

Board Member

Ketan Patel

Board Member

Jake Simson

Board Member

Krishna Polu

President & Chief Operating Officer

Ryan Cohlhepp

Chief Executive Officer

Claire Mazumdar

Senior Scientific Advisor

Seng-Lai "Thomas" Tan

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo